Machine Learning

A new class of AI-driven blood tests can detect lung cancer recurrence years before imaging, shaking up patient care and the multi-billion dollar diagnostics market.

Illumina's new partnership with MyOme targets a $200B healthcare savings prize. But can AI-driven genomics overcome the hurdles to deliver resilient returns?

From spreadsheets to algorithms, RedCloud aims to overhaul the $14.6T FMCG market with AI. A financial turnaround now fuels its global expansion.

With a new C-suite, MarketCast is overhauling its strategy, promising a future AI platform to finally connect creative with real business outcomes.

Inotiv partners with AI firm VUGENE, but this is no simple tech deal. It's a high-stakes move to compete in a market dominated by AI-powered giants.

S&P Global's latest report confirms Fluence's top-three status in the BESS market, driven by strategic execution and the surging demand for grid stability.

Oracle's new leadership status highlights a major industry shift. Clean, AI-managed data is now the core asset for efficient and resilient utility operations.

TIME's honor for AI's creators reveals a hidden truth: the digital revolution's massive energy and hardware needs are supercharging the race for minerals.

Engineering giant Amentum will leverage advanced tech in a decade-long, multi-billion dollar effort to help nations combat nuclear and biological threats.

A new contract for its explainable AI in a pivotal Phase 3 trial shows NetraMark is helping Big Pharma de-risk its most expensive R&D phase.

Early results for INT230-6 show 50% fewer severe side effects, raising hopes for a treatment that could eliminate the toxic 'red devil' chemo.

Nasdaq-listed Society Pass is ditching its e-commerce roots for the AI gold rush. Is this a savvy M&A masterstroke or a risky gamble in a capital-heavy arena?

Public safety agencies are drowning in data. A new alliance brings advanced AI tools to the front lines to solve cases faster and ensure evidence integrity.

Beyond services, Charles River is building an ecosystem. We look at how its incubator nurtures startups and secures its own future in advanced medicine.

New Phase 2 data shows Elicio's off-the-shelf therapy ELI-002 7P induces "antigen spreading," creating a personalized anti-tumor response.

Beyond a simple acquisition, ZenaTech is executing a bold strategy to digitize the American West, transforming old-guard industries with a DaaS network.

The latest O-RAN PlugFest showcases major AI integration and a shift to live networks, but the path to widespread commercial adoption remains complex.

A tech-driven 'anti-CRO' and a clinical accelerator have joined forces. Can their integrated model finally fix the broken drug development pipeline?

Roivant Sciences reveals accelerated timelines for key drugs and a bold three-year growth plan, pivoting its unique 'Vant' model toward commercialization.

Praxis Precision Medicines secures a clear path to market for its rare epilepsy drug, blending genetic science with a savvy regulatory strategy.